BlackRock TCP Capital (TCPC) to pay $0.36 on Dec 31, 2019; Incyte (INCY) Had 6 Analysts Last Week

Incyte Corporation (NASDAQ:INCY) Logo

Among 9 analysts covering Incyte (NASDAQ:INCY), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Incyte has $11100 highest and $82 lowest target. $95.11’s average target is 3.93% above currents $91.51 stock price. Incyte had 18 analyst reports since July 31, 2019 according to SRatingsIntel. The firm has “Hold” rating by RBC Capital Markets given on Thursday, October 17. JMP Securities maintained Incyte Corporation (NASDAQ:INCY) rating on Monday, September 30. JMP Securities has “Market Outperform” rating and $11000 target. JMP Securities maintained Incyte Corporation (NASDAQ:INCY) rating on Thursday, October 24. JMP Securities has “Buy” rating and $110 target. The company was upgraded on Thursday, September 5 by Oppenheimer. The firm has “Buy” rating given on Wednesday, July 31 by Nomura. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, July 31. Piper Jaffray maintained Incyte Corporation (NASDAQ:INCY) rating on Tuesday, October 29. Piper Jaffray has “Buy” rating and $95 target. The firm has “Buy” rating by J.P. Morgan given on Tuesday, October 29. JMP Securities reinitiated Incyte Corporation (NASDAQ:INCY) rating on Thursday, September 5. JMP Securities has “Market Outperform” rating and $10700 target. The stock of Incyte Corporation (NASDAQ:INCY) earned “Buy” rating by Piper Jaffray on Monday, October 14. See Incyte Corporation (NASDAQ:INCY) latest ratings:

27/11/2019 Broker: BidaskScore Rating: Buy Upgrade
29/10/2019 Broker: J.P. Morgan Rating: Buy New Target: $91 Maintain
29/10/2019 Broker: Piper Jaffray Rating: Buy New Target: $95 Maintain
24/10/2019 Broker: JMP Securities Rating: Buy New Target: $110 Maintain
17/10/2019 Broker: RBC Capital Markets Rating: Hold New Target: $82 Maintain
14/10/2019 Broker: Piper Jaffray Rating: Buy New Target: $95 Maintain
14/10/2019 Broker: Mizuho Rating: Buy New Target: $95 Maintain
13/10/2019 Broker: Cowen & Co Rating: Buy Maintain
10/10/2019 Broker: BidaskScore Rating: Hold Upgrade
03/10/2019 Broker: Mizuho Rating: Buy New Target: $95.0000 Initiates Coverage On

BlackRock TCP Capital Corp (NASDAQ:TCPC) is expected to pay $0.36 on Dec 31, 2019. (NASDAQ:TCPC) shareholders before Dec 16, 2019 will receive the $0.36 dividend. BlackRock TCP Capital Corp’s current price of $14.44 translates into 2.49% yield. BlackRock TCP Capital Corp’s dividend has Dec 17, 2019 as record date. Nov 6, 2019 is the announcement. The stock increased 0.21% or $0.03 during the last trading session, reaching $14.44. About 507,758 shares traded or 125.10% up from the average. BlackRock TCP Capital Corp. (NASDAQ:TCPC) has 0.00% since December 15, 2018 and is . It has by 0.00% the S&P500. Some Historical TCPC News: 09/05/2018 – TCP Capital: 1Q Total Investment Income $44.2 Million, or 75c Per Share; 17/04/2018 – BlackRock says to buy private credit investor Tennenbaum Capital; 02/05/2018 – Wells Fargo Advisors LLC Exits Position in TCP Capital; 17/04/2018 – BlackRock, Inc. to Acquire Private Credit Manager Tennenbaum Capital Partners; 03/04/2018 S&P REVISES TCP CAPITAL CORP. OUTLOOK TO ‘NEGATIVE’ FROM ‘STABLE’; RATING ‘BBB-‘; 09/05/2018 – TCP Capital 1Q EPS 46c; 17/04/2018 – BLACKROCK INC BLK.N – TERMS WERE NOT DISCLOSED; 09/05/2018 – TCP Capital: Total Assets $1,665.6 Million as of March 31; 09/05/2018 – TCP CAPITAL 1Q NAV/SHR $14.90; 12/04/2018 – TCP Capital Corp. Schedules Earnings Release and Conference Call for the First Quarter Ended March 31, 2018

The stock decreased 1.44% or $1.34 during the last trading session, reaching $91.51. About 1.85 million shares traded or 67.82% up from the average. Incyte Corporation (NASDAQ:INCY) has risen 45.13% since December 15, 2018 and is uptrending. It has outperformed by 45.13% the S&P500. Some Historical INCY News: 08/03/2018 – Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering Intern; 07/05/2018 – PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA; 06/04/2018 – Keytruda/epacadostat combo crashes in PhIII melanoma study, raising questions about the future of IDO for Incyte $INCY; 17/04/2018 – So #AACR18 kept $INCY epacadostat + durvalumab combo ECHO-203 data in the official press program; 09/04/2018 – KEYTRUDA MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3; 16/05/2018 – Merck:Evidence Continues to Support the Role of KEYTRUDA as a Foundational Treatment for Many Types of Cancer; 23/04/2018 – INCYTE CORP INCY.O – U.S. FDA ADVISORY COMMITTEE DID NOT RECOMMEND APPROVAL OF 4-MG DOSE OF BARICITINIB; 06/04/2018 – Nektar Therapeutics Is Less Sweet After Incyte’s Drug Sours; 23/04/2018 – FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Act; 08/05/2018 – ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA

Investors sentiment increased to 1.49 in Q3 2019. Its up 0.26, from 1.23 in 2019Q2. It is positive, as 46 investors sold Incyte Corporation shares while 102 reduced holdings. 55 funds opened positions while 166 raised stakes. 187.63 million shares or 0.69% less from 188.94 million shares in 2019Q2 were reported. Norinchukin Bank The invested in 0.03% or 26,370 shares. Chevy Chase Tru holds 149,066 shares or 0.05% of its portfolio. 142 are owned by Nuwave Investment Management. Farmers And Merchants Investments Inc holds 83 shares. Sector Gamma As holds 4.34% or 345,893 shares. Captrust Financial holds 0% or 400 shares in its portfolio. Blackrock Inc reported 0.05% stake. Capital International Ltd Ca invested in 0.67% or 59,842 shares. Zacks Investment Management invested in 16,361 shares or 0.02% of the stock. Allsquare Wealth Ltd Com has invested 0.01% in Incyte Corporation (NASDAQ:INCY). Oak Ridge Invests Ltd Llc invested 0.19% in Incyte Corporation (NASDAQ:INCY). The New Jersey-based Bessemer Gru Inc has invested 0.14% in Incyte Corporation (NASDAQ:INCY). B And T Cap Dba Alpha Cap reported 0% in Incyte Corporation (NASDAQ:INCY). Weiss Multi accumulated 0.05% or 33,000 shares. Omers Administration Corp holds 0.06% or 84,400 shares.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $20.00 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It has a 48.91 P/E ratio. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: which released: “Update: Incyte (NASDAQ:INCY) Stock Gained 36% In The Last Year – Yahoo Finance” on November 19, 2019, also with their article: “Incyte (INCY) Is Up 1.88% in One Week: What You Should Know – Nasdaq” published on November 20, 2019, published: “INCY Crosses Above Average Analyst Target – Nasdaq” on December 02, 2019. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: and their article: “Noteworthy Monday Option Activity: BANC, INCY, HAS – Nasdaq” published on November 25, 2019 as well as‘s news article titled: “Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report? – Nasdaq” with publication date: November 28, 2019.

BlackRock TCP Capital Corp. is a business development firm specializing in direct equity and debt investments in middle-market, senior secured loans, junior loans, originated loans, mezzanine, senior debt instruments, bonds, and secondary-market investments. The company has market cap of $849.00 million. It seeks to invest in the United States. It has a 27.61 P/E ratio. The fund typically invests between $10 million and $35 million in companies with enterprise values between $100 million and $1500 million.

BlackRock TCP Capital Corp. (NASDAQ:TCPC) Institutional Positions Chart